Alzheimer’s Disease/Dementia News

Older adults with a coronary artery calcium score of 0 had more favorable aging indices, including normal cognitive function, vascular function and better hearing, compared with those with CAC scores of 1,000 or greater, data show.

A program geared toward diabetes management in the primary care setting helped to reduce patients’ risk for dementia — including Alzheimer’s disease — according to researchers.

The FDA has granted breakthrough therapy designation to latozinemab, an investigational therapeutic designed to block sortilin and elevate progranulin to treat frontotemporal dementia with a progranulin gene mutation.

For those with either acute ischemic stroke or intracerebral hemorrhage, risk of dementia was three times higher after the first year and remained elevated as many as 20 years after, a speaker said at the International Stroke Conference.

Silo Pharma will advance a portfolio of four drugs in its 2024 clinical pipeline, targeting conditions related to mental health, chronic pain and neurology.

Biogen announced a reprioritization of resources regarding its pipeline of therapeutics to address Alzheimer’s disease, deciding to discontinue development of Aduhelm and choosing to advance Leqembi.

Isaac Health has raised $5.7 million to help identify and care for individuals with different cognitive and brain health conditions in the United States.

A plasma phosphorylated-tau217 assay demonstrated a high degree of accuracy in identifying biomarkers consistent with Alzheimer’s disease-related pathology, according to research from JAMA Neurology.

A Houston-based neurohealth company has received a patent for its non-invasive, frequency-based deep brain stimulation device to address a range of psychiatric and neurologic conditions.

IGC Pharma has announced that dosing has commenced at one of its sites participating in a phase 2b clinical trial of a combination therapy for agitation in dementia related to Alzheimer’s disease.